Siyao Du

Siyao Du

Auto-generated profile, based on publicly available information

Siyao Du

Department of Radiology, The First Hospital of China Medical University, Shenyang, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LGLiangcun Guo
Liangcun Guo
SDSiyao Du
Siyao Du
SGSi Gao
Si Gao
RZRuimeng Zhao
Ruimeng Zhao
GHGuoliang Huang
Guoliang Huang
LZLina Zhang
Lina Zhang
Objective: To investigate the value of delta-radiomics after the first cycle of neoadjuvant chemotherapy (NAC) using dynamic contrast-enhanced (DCE) MRI for early prediction of pathological complete response (pCR) in patients with breast cancer. Methods: From September 2018 to May 2021, a total of 140 consecutive patients (training, n = 98: validation, n = 42), newly diagnosed with breast cancer who received NAC before surgery, were prospectively enrolled. All patients underwent DCE-MRI at pre-NAC (pre-) and after the first cycle (1st-) of NAC. Radiomic features were extracted from the postcontrast early, peak, and delay phases. Delta-radiomics features were computed in each contrast phases. Least absolute shrinkage and selection operator (LASSO) and a logistic regression model were used to select features and build models. The model performance was assessed by receiver operating characteristic (ROC) analysis and compared by DeLong test. Results: The delta-radiomics model based on the early phases of DCE-MRI showed a highest AUC (0.917/0.842 for training/validation cohort) compared with that using the peak and delay phases images. The delta-radiomics model outperformed the pre-radiomics model (AUC = 0.759/0.617, p = 0.011/0.047 for training/validation cohort) in early phase. Based on the optimal model, longitudinal fusion radiomic models achieved an AUC of 0.871/0.869 in training/validation cohort. Clinical-radiomics model generated good calibration and discrimination capacity with AUC 0.934 (95%CI: 0.882, 0.986)/0.864 (95%CI: 0.746, 0.982) for training and validation cohort. Delta-radiomics based on early contrast phases of DCE-MRI combined clinicopathology information could predict pCR after one cycle of NAC in patients with breast cancer.

1 January 2024 in Radiology
Verified
Journal Article
Closed access
SDSiyao Du
Siyao Du
SGSi Gao
Si Gao
MWMengfan Wang
Mengfan Wang
LZLina Zhang
Lina Zhang

2 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYanting Liang
Yanting Liang
ZWZhitao Wei
Zhitao Wei
YDYi Dai
Yi Dai
XCXiaobo Chen
Xiaobo Chen
SDSiyao Du
Siyao Du
ZSZhenwei Shi
Zhenwei Shi
Breast cancer diagnosis using magnetic resonance imaging remains limited by high false-positive rates and substantial inter-reader variability, especially for lesions classified as Breast Imaging Reporting and Data System (BI-RADS) category 4, often leading to unnecessary biopsies. Here we show that the BI-RADS 4 Lesions Analysis System (BL4AS), an artificial intelligence system powered by foundation models and leveraging the rich spatiotemporal information of dynamic contrast-enhanced MRI, addresses these diagnostic challenges. Developed on a multicenter dataset of 2,803 lesions from 2,686 female patients, BL4AS demonstrates robust performance with areas under the curve of 0.892-0.930 and significantly outperforms radiologists in specificity (0.889 versus 0.491). BL4AS-assisted interpretation significantly improves diagnostic accuracy for both senior and junior radiologists, reducing inter-reader variability by 24.5% and decreasing false-positive rates by 27.3%. BL4AS further stratifies lesions into subcategories (4 A, 4B and 4 C) for refined risk assessment, offering a practical tool for precision breast cancer management.

27 November 2025 in Expert Systems with Applications
Verified
Journal Article
Closed access
YLYaoqi Liu
Yaoqi Liu
SDSiyao Du
Siyao Du
ZXZeyan Xu
Zeyan Xu
ZZZhen Zhang
Zhen Zhang
ZWZhitao Wei
Zhitao Wei
WLWenbin Liu
Wenbin Liu

3 August 2023
Verified
Conference Paper
Closed access
SDSiyao Du
Siyao Du
MWMengfan Wang
Mengfan Wang
SLShasha Liu
Shasha Liu
XBXiaoqian Bian
Xiaoqian Bian
XCXinyue Chen
Xinyue Chen
LZLina Zhang
Lina Zhang
In this study, we compared first-order features of six DWI models in predicting the HER-2 expression in breast invasive ductal carcinoma, including conventional mono-exponential model derived parameter ADC, IVIM derived parameters (D, Dstar, f), DKI derived parameters (D, K), SEM derived parameters (DDC, α), FROC derived parameters (D, β, mu), CTRW derived parameters (D, α, β), and a comprehensive diagnostic logistic regression model was established to improve the diagnostic performance. We found that CTRM and IVIM derived first-order features demonstrated the powerful performance, and their combination reached the highest performance. The finding has a great value in breast cancer treatment.

3 August 2023
Verified
Conference Paper
Closed access
SDSiyao Du
Siyao Du
MWMengfan Wang
Mengfan Wang
SLShasha Liu
Shasha Liu
XBXiaoqian Bian
Xiaoqian Bian
XCXinyue Chen
Xinyue Chen
LZLina Zhang
Lina Zhang
In this study, we built a support vector machine (SVM) model based on quantitative parameters of continuous-time random-walk (CTRW) diffusion model in predicting the human epidermal growth factor receptor-2 (HER-2) expression in breast invasive ductal carcinoma. An AUC of 0.753 was achieved, which may have a great potential in future clinical practice.